Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2086 to 2100 of 9128 results

  1. Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

    Technology appraisal Reference number: TA582 Published:  24 May 2019

    Technology appraisal guidance
    In development

  2. Fenfluramine for treating seizures associated with Dravet syndrome in people under 2 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Secukinumab for treating moderate to severe hidradenitis suppurativa in people 12 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Mirikizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Bee venom immunotherapy for generalised or systemic IgE-mediated allergic reactions to bee venom

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Wasp venom immunotherapy for treating wasp venom allergy

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    In development Reference number: GID-HTG10172 Expected publication date: TBC

    HealthTech guidance
    In development

  8. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    In development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 21 July 2026.

    Technology appraisal guidance
    In consultation

  10. Polyendocrine Metabolic Ovarian Syndrome (PMOS): draft guidance

    We are listening to your views on this NICE guideline. Comments close 11 August 2026.

    NICE guideline
    In consultation

  11. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

    Awaiting development Reference number: GID-TA12518 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Excimer laser trabeculotomy for open angle glaucoma

    Awaiting development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  13. In-situ abdominal normothermic regional perfusion to preserve donor livers during retrieval for transplantation after controlled circulatory death: interventional procedure consultation

    We are listening to your views on this HealthTech guidance. Comments close 28 July 2026.

    In consultation

  14. Headaches (update): Prophylactic treatment of migraine - Candesartan: draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 21 July 2026.

    NICE guideline
    In consultation

  15. Transvaginal radiofrequency ablation for symptomatic uterine fibroids

    In development Reference number: GID-HTG10538 Expected publication date: TBC

    HealthTech guidance
    In development